Summary
Recent clinical data, including findings suggest a complex link between GLP-1 use and bone health. While these medications appear to protect the bone density of patients with Type 2 diabetes, non-diabetic users face a significantly higher risk of osteoporosis and osteomalacia. Experts believe rapid weight loss and nutritional gaps drive this skeletal decline, highlighting the need for resistance training and DEXA monitoring.
The meteoric rise of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro has fundamentally shifted how we approach metabolic health. While these “miracle drugs” have proven effective at shedding pounds and stabilizing blood sugar, new concerns are emerging now that patients have spent enough time on the medication to analyze longer-term effects.
For the past few years, the conversation surrounding GLP-1s was centered almost exclusively on cardiovascular benefits and glycemic control. However, as the patient population expands from those with Type 2 diabetes to millions of adults using the medication for primary weight loss, the long-term impact on the musculoskeletal system is finally coming under the microscope. The latest research indicates a complex, “dual reality” where these drugs may actually protect the bones of some patients while posing a silent risk to others.
The “Diabetes Protective” Effect
Historically, GLP-1s were viewed as bone-neutral or even bone-protective. This holds true for many patients with Type 2 diabetes.
Diabetes itself is a “bone-thinning” disease. According to a 2024–2025 Epic Research study of 2 million patients, GLP-1 use in diabetics was associated with an 8.7% lower risk of osteoporosis compared to non-users.
By controlling blood sugar and reducing systemic inflammation, GLP-1s may help mitigate the bone damage typically caused by chronic high glucose. Even when patients with diabetes lost weight on these drugs, their increase in osteoporosis risk was consistently smaller than that of patients losing weight via other methods.
The Emerging Risk for Non-Diabetics
The narrative changes significantly for patients using GLP-1s primarily for weight loss. The same Epic Research study found that adults without diabetes on GLP-1s who maintained a stable weight had a 22% higher risk of osteoporosis compared to those on other weight-loss medications.
Another study showed that over a five-year period, GLP-1 users had a slightly higher incidence of osteoporosis (4.1% vs. 3.2% in controls) and a rare bone-softening condition called osteomalacia (which occurred at double the rate of the control group).
Researchers believe the correlation may not be a “toxic” effect of the GLP1’s, but rather a byproduct of how the body responds to rapid weight loss:
- Mechanical Unloading: Bones are living tissue that stay strong by carrying weight. When body mass drops rapidly, the “load” on the bones decreases, signaling the body that it doesn’t need as much bone density.
- Nutritional Gaps: GLP-1s work by suppressing appetite. If patients are not intentional about their intake, they may experience “malnutrition of the obese,” where they lose weight but fail to consume enough protein, calcium, and Vitamin D.
- Muscle Loss (Sarcopenia): Rapid weight loss often includes the loss of lean muscle. Muscle pulls on bone during movement; without that tension, bone density can decline.
A Balanced Perspective: Context Matters
It is vital to note that these risks, while statistically significant, are relatively small in absolute terms. For most patients, the cardiovascular and metabolic benefits of losing 15–20% of their body weight far outweigh a 1% absolute increase in osteoporosis risk.
Furthermore, some research still points to a “fracture paradox.” Despite lower bone density in some studies, others such as a late 2025 report from the American Osteopathic Academy of Orthopedics found that GLP-1 users actually had lower odds of experiencing a fracture. This could be because lighter patients are less likely to fall or because the mechanical stress of carrying excess weight is more dangerous than the slight loss of bone mineral density.
Knowledge is Prevention
The “long-term” impact of GLP-1s is a story still being written. We are only now reaching the 5-to-10-year follow-up mark for the current generation of these drugs.
For patients and providers, the takeaway is not to fear the medication, but to work with your doctor to mitigate the bone health risks. Experts now recommend:
- Baseline DEXA Scans: Getting a bone density baseline before starting long-term GLP-1 therapy.
- Resistance Training: Prioritizing strength training to signal the bones and muscles to stay strong.
- Aggressive Nutrition: Ensuring high protein and Vitamin D intake to offset the “starvation” signals the body receives during rapid weight loss.
As we move forward, Health Insiders know that the goal is “Healthy Weight Loss,” not just “Weight Loss.” Protecting the frame is just as important as reducing the load.
Subscribe to The Health Insider for ongoing health updates right to your inbox.
~ Read more from The Health Insider ~
- GLP-1s and Bone Health: Potential Risks for Non-Diabetics
New studies reveal a 22% higher osteoporosis risk for non-diabetics on GLP-1s. Learn how these weight-loss drugs may impact your skeletal strength. - Protecting Canada’s Kids: The Hidden Risk in Your Child’s Favourite Cartoon SnacksA Canadian report finds many kids’ snacks with cartoon characters are high in sugar, sodium or fat, raising concerns about food marketing to children.
- At-Home Sperm Testing: As Accurate As In-Clinic?Skip the clinic. Learn how Canadian mail-in kits bypass the “one-hour rule” with 99% accuracy and which provincial credits cover the cost.
- Endometriosis and the Immune System: What New Research Is ShowingNew research suggests people with endometriosis may face higher odds of autoimmune disease. Here’s what scientists know so far.
- Beyond Red & Green: New Tech for Colour BlindnessOver 1.5 million Canadians live with colour blindness. Discover the science, daily challenges, and the high-tech tools changing how they see.
- Health Canada Approves Ozempic to Reduce Heart Attack and Stroke RiskHealth Canada expands Ozempic approval to include reducing the risk of heart attacks and strokes in adults with type 2 diabetes and heart or kidney disease.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
